Ignite Creation Date:
2025-12-25 @ 3:27 AM
Ignite Modification Date:
2025-12-26 @ 2:08 AM
Study NCT ID:
NCT07296705
Status:
RECRUITING
Last Update Posted:
2025-12-22
First Post:
2025-09-26
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Sponsor:
Fujian Medical University Union Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-10-25
Start Date Type:
ACTUAL
Primary Completion Date:
2027-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-12
Completion Date Type:
ESTIMATED
First Submit Date:
2025-09-26
First Submit QC Date:
None
Study First Post Date:
2025-12-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-08
Last Update Post Date:
2025-12-22
Last Update Post Date Type:
ESTIMATED